SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Inovio Pharmaceuticals, Inc. (INO)

INO RSS Feed
Add INO Price Alert      Hide Sticky   Hide Intro
Moderator: Ubertino
Search This Board: 
Last Post: 12/12/2017 2:53:23 PM - Followers: 408 - Board type: Free - Posts Today: 0

Logo: Inovio

www.inovio.com/

http://finance.yahoo.com/q/ks?s=INO

http://finance.aol.com/company/inovio-biomedical-corporation/ino/ase/institutional-ownership

F
ebruary 12, 2014 Inovio CEO Dr. Joseph Kim rings bell to open trading on NYSE- http://www.youtube.com/watch?v=95yO6hFpbUM


Float: 97.65 M

Shares Outstanding: 127.26 M


Inovio Biomedical Corporation engages in the design, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The company?s SynCon technology enables the design of DNA-based vaccines capable of providing cross-protection against evolving, unmatched strains of pathogens, such as influenza. Inovio?s proprietary electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. The company also has access to formulation and manufacturing expertise, and technology through its controlling ownership in VGX International. Inovio?s clinical programs include trials for HPV/cervical cancer (therapeutic) and HIV vaccines; and an IND has been filed for an avian influenza vaccine. Its partners and collaborators include Roche,Merck, Tripep, University of Southampton, University of Pennsylvania, HIV Vaccines Trial Network, and National Microbiology Laboratory of the Public Health Agency of Canada. The company was formerly known as Genetronics Biomedical Corp. and changed its name to Inovio Biomedical Corporation in March 2005. The company was founded in 1983 and is based in San Diego, California.

Currently Inovio has 12 clinical studies ( HIV, Influenza, Malaria, Hepatitis B, Hepatitis C, Breast and Lung cancer, Prostate Cancer, Head and Neck cancer, Cervical Cancer, Cervical dysplasia caused by HPV) ongoing from preclinical to phase 2.
 
Sep 10, 2013
Roche and Inovio Pharmaceuticals partner on Inovio's prostate cancer and hepatitis B immunotherapy products. Roche will make an upfront payment of USD $10 million to Inovio. Roche will also provide preclinical R&D support and payments for near-term regulatory milestones as well as payments upon reaching certain development and commercial milestones potentially up to USD $412.5 million. Additional development milestone payments could also be made to Inovio if Roche pursues other indications with INO-5150 or INO-1800.  In addition, Inovio is entitled to receive up to double-digit tiered royalties on product sales.

VGX-3100-Phase 2 Clinical Trial initiated for the treatment Cervical dysplasia (cervical intraepithelial neoplasia or CIN) caused by HPV
Top line data release Mid 2014
May 13, 2014:  Inovio Pharmaceuticals Acquires Early Stage DNA Therapies to Treat Alzheimer's and Multiple Sclerosis
http://finance.yahoo.com/news/inovio-pharmaceuticals-acquires-early-stage-080000624.html?.tsrc=applewf

May 23, 2014: Inovio Pharmaceuticals Announces 1 For 4 Reverse Split
http://finance.yahoo.com/news/inovio-pharmaceuticals-announces-1-4-080000629.html
1-for-4 reverse stock split shall become effective at 5 P.M., Thursday, June 5, 2014, and trading of the Company's common stock on a post-reverse split basis shall commence on Friday, June 6, 2014.


Inovio’s goal is to revolutionize vaccines. With best-in-class immune responses from multiple vaccines in different disease areas, our synthetic vaccine technology is making big strides toward this important goal.



 
 



 

SureTrader
Interactive Brokers Advertisement
INO
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#4698  Sticky Note Please stay on topic. The only topic to IH Dan (Retired) 08/02/13 01:15:33 PM
#14118   Sure not helping today: chmcnfunds 12/12/17 02:53:23 PM
#14117   Back in INO @ $4.25 on day when chmcnfunds 12/12/17 02:16:32 PM
#14116   The cure rate of HPV infection without any avav1001 12/09/17 02:49:53 AM
#14115   Placebo Question WWIII 12/08/17 04:44:39 PM
#14114   Thanks for the abstract about the synergism with avav1001 11/30/17 11:44:48 PM
#14113   I believe that is a different study. Subsequently chmcnfunds 11/30/17 08:29:57 AM
#14112   news, news and more news radly 11/29/17 09:11:31 PM
#14111   Here is the abstract of the publication. The avav1001 11/29/17 09:05:57 PM
#14110   You know I sold early, but not at chmcnfunds 11/28/17 08:36:41 AM
#14109   I agree. What the heck will it take radly 11/27/17 09:32:57 PM
#14108   This stock is unbelievable. Put out news of DrStockonomics 11/27/17 05:13:43 PM
#14107   Sold @ $4.80, far too soon, as surged chmcnfunds 11/27/17 10:19:26 AM
#14106   Inovio Pharmaceuticals SynCon® TERT Cancer Immunotherapy Combined with chmcnfunds 11/27/17 08:14:31 AM
#14105   Below 0.99 in 2018. arvitar 11/24/17 08:50:09 PM
#14104   The day they get FDA approval on any Ubertino 11/24/17 12:42:27 PM
#14103   When, in 2035? radly 11/24/17 10:15:14 AM
#14102   I believe you are correct, but I surely chmcnfunds 11/24/17 07:53:59 AM
#14101   Looking good. Ubertino 11/23/17 09:37:56 AM
#14100   Like INO's vaccines, Nektar's NKTR-214 also seems to avav1001 11/23/17 01:50:19 AM
#14099   Hot Stock Evaluation – Inovio Pharmaceuticals, Inc. (NASDAQ: INO) chmcnfunds 11/17/17 11:05:06 AM
#14098   Q3 2017 Inovio Pharmaceuticals Inc Earnings Call chmcnfunds 11/17/17 10:47:08 AM
#14097   That’s called “doing due dilligence” and searching Google. TomP1 11/14/17 01:33:12 PM
#14096   Back in INO @ $4.30 today (but not chmcnfunds 11/14/17 11:37:22 AM
#14095   I have no scientific expertise. Is Cincinnatus 11/14/17 10:51:40 AM
#14094   This stock sucks! radly 11/13/17 07:26:13 PM
#14093   Sold @ $4.75 to take profits. Definitely looking chmcnfunds 11/10/17 03:57:31 PM
#14092   Entered yesterday @ $4.51. Got to believe at chmcnfunds 11/10/17 08:42:04 AM
#14091   * * $INO Video Chart 11-09-17 * * ClayTrader 11/09/17 04:49:07 PM
#14090   Nope, she's going down big tomorrow. Might break DrStockonomics 11/08/17 10:39:24 PM
#14089   I hope the lower revenue is already factored radly 11/08/17 06:55:20 PM
#14088   garbage still dropping! radly 11/07/17 05:04:56 PM
#14087   7. the Filer is authorized to issue up Ubertino 11/03/17 05:08:03 PM
#14086   Yes, I've been watching this stock for a DarkLady 11/03/17 03:28:57 PM
#14085   Dr. J. Joseph Kim, Inovio's President and Chief radly 11/01/17 07:34:23 PM
#14084   https://www.thestreet.com/story/14361971/1/inovio-pharmaceuticals-is-now-oversol radly 10/28/17 09:06:10 PM
#14083   Is it? Let's see if we can rationalize MasterK9 10/27/17 11:03:31 AM
#14082   Sad, down over a buck in the last radly 10/26/17 08:32:29 PM
#14081   So they cure cancer and viral scourge - Ubertino 10/25/17 10:24:51 AM
#14080   I wouldn’t trust anyone on a message board DrStockonomics 10/25/17 10:12:56 AM
#14079   I agree, in part. However, it is much MasterK9 10/25/17 10:01:45 AM
#14078   It turns around when/if they finally get something DrStockonomics 10/24/17 10:04:17 PM
#14077   Last few trading sessions???? radly 10/24/17 06:52:55 PM
#14076   There are many who continue to post negative MasterK9 10/24/17 01:40:40 PM
#14075   I love the US Army! Ubertino 10/24/17 12:20:31 PM
#14074   Market must hate INO and the US army. lol radly 10/24/17 12:16:45 PM
#14073   RBC Capital initiates on 10/18/17 with an Outperform MasterK9 10/24/17 10:11:36 AM
#14072   The US Army picks Inovio!! Ubertino 10/24/17 09:18:26 AM
#14071   flippers dream here again. loading up $$$$ harry crumb 10/23/17 05:36:16 PM
#14070   * * $INO Video Chart 10-23-17 * * ClayTrader 10/23/17 05:10:36 PM
#14069   Govx 3 market cap better pipe federally funded akamaii 10/23/17 01:23:21 PM
PostSubject